Advanced Biomedical Technologies Inc. (ABMT) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
200 PARK AVENUE, SUITE 1700 NEW YORK, NY 10166 |
| State of Incorp. | |
| Fiscal Year End | October 31 |
| Industry (SIC) | 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 7/31/2021 Q3 | 4/30/2021 Q2 | 1/31/2021 Q1 | 10/31/2020 Q4 | 7/31/2020 Q3 | 4/30/2020 Q2 | 1/31/2020 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 6,008 | 8,491 | 201,664 | 14,474 | 10,640 | 8,086 | |||
| Cash and cash equivalent | 6,008 | 8,491 | 201,664 | 14,474 | 10,640 | 8,086 | |||
| Inventory, net of allowances, customer advances and progress billings | 159,011 | 122,221 | 100,026 | 80,362 | 64,509 | 49,399 | |||
| Inventory | 159,011 | 122,221 | 100,026 | 80,362 | 64,509 | 49,399 | |||
| Other undisclosed current assets | 53,151 | 56,398 | 29,260 | 34,717 | 36,404 | 59,940 | |||
| Total current assets: | 218,170 | 187,110 | 330,950 | 129,553 | 111,553 | 117,425 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 13,338 | 22,392 | 32,802 | 42,308 | 52,483 | 64,518 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 147,180 | 122,290 | 105,474 | 109,778 | 112,321 | 95,959 | |||
| Total noncurrent assets: | 160,518 | 144,682 | 138,276 | 152,086 | 164,804 | 160,477 | |||
| TOTAL ASSETS: | 378,688 | 331,792 | 469,226 | 281,639 | 276,357 | 277,902 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | |||||||||
| Other undisclosed accounts payable and accrued liabilities | |||||||||
| Due to related parties | 5,350,516 | 5,249,202 | 4,705,512 | 5,083,314 | 5,118,899 | 5,044,984 | |||
| Other undisclosed current liabilities | 2,997,312 | 2,911,613 | 3,158,483 | 2,181,303 | 1,864,415 | 1,852,472 | |||
| Total current liabilities: | 8,347,828 | 8,160,815 | 7,863,995 | 7,264,617 | 6,983,314 | 6,897,456 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 3,690 | 7,029 | 10,029 | 13,092 | 22,301 | ||||
| Operating lease, liability | 3,690 | 7,029 | 10,029 | 13,092 | 22,301 | ||||
| Total noncurrent liabilities: | 7,380 | 7,029 | 20,058 | 26,184 | 44,602 | ||||
| Total liabilities: | 8,347,828 | 8,168,195 | 7,878,053 | 7,284,675 | 7,009,498 | 6,942,058 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (7,969,140) | (7,832,713) | (7,401,798) | (6,993,007) | (6,720,049) | (6,641,855) | |||
| Common stock | 702 | 702 | 702 | 700 | 700 | 698 | |||
| Additional paid in capital | 2,831,658 | 2,827,832 | 2,824,279 | 2,782,541 | 2,779,132 | 2,771,527 | |||
| Accumulated other comprehensive income (loss) | (196,687) | (245,541) | 21,425 | 280,115 | 355,657 | 234,073 | |||
| Accumulated deficit | (10,617,497) | (10,428,408) | (10,256,364) | (10,063,030) | (9,857,805) | (9,648,153) | |||
| Other undisclosed equity, attributable to parent | 12,684 | 12,702 | 8,160 | 6,667 | 2,267 | ||||
| Total equity: | (7,969,140) | (7,832,713) | (7,401,798) | (6,993,007) | (6,720,049) | (6,641,855) | |||
| Other undisclosed liabilities and equity | (3,690) | (7,029) | (10,029) | (13,092) | (22,301) | ||||
| TOTAL LIABILITIES AND EQUITY: | 378,688 | 331,792 | 469,226 | 281,639 | 276,357 | 277,902 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 7/31/2021 Q3 | 4/30/2021 Q2 | 1/31/2021 Q1 | 10/31/2020 Q4 | 7/31/2020 Q3 | 4/30/2020 Q2 | 1/31/2020 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 95 | 47,233 | 62,336 | 961 | 60,501 | |||
| Revenue from related parties | 47,233 | |||||||
| Cost of revenue | (10,147) | (33,127) | ||||||
| Other undisclosed gross profit | (32) | (17,986) | (820) | (95) | ||||
| Gross profit: | 63 | 37,086 | 44,350 | 141 | (95) | 27,374 | ||
| Operating expenses | (113,213) | (125,728) | (154,554) | (116,582) | (120,239) | (127,019) | ||
| Operating loss: | (113,150) | (88,642) | (110,204) | (116,441) | (120,334) | (99,645) | ||
| Nonoperating income (expense) | (75,939) | (83,402) | (83,130) | (88,784) | (89,318) | 35,856 | ||
| Interest and debt expense | (314) | (73,018) | (3,490) | (3,409) | (3,407) | (3,389) | ||
| Loss from continuing operations before equity method investments, income taxes: | (189,403) | (245,062) | (196,824) | (208,634) | (213,059) | (67,178) | ||
| Other undisclosed income from continuing operations before income taxes | 314 | 73,018 | 3,490 | 3,409 | 3,407 | 3,389 | ||
| Loss from continuing operations: | (189,089) | (172,044) | (193,334) | (205,225) | (209,652) | (63,789) | ||
| Loss before gain (loss) on sale of properties: | (189,089) | (172,044) | (193,334) | (205,225) | (209,652) | (63,789) | ||
| Net loss available to common stockholders, diluted: | (189,089) | (172,044) | (193,334) | (205,225) | (209,652) | (63,789) | ||
Comprehensive Income (USD)Annual | Quarterly
| 7/31/2021 Q3 | 4/30/2021 Q2 | 1/31/2021 Q1 | 10/31/2020 Q4 | 7/31/2020 Q3 | 4/30/2020 Q2 | 1/31/2020 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (189,089) | (172,044) | (193,334) | (205,225) | (209,652) | (63,789) | ||
| Other comprehensive income (loss) | 48,854 | (266,966) | (258,690) | (75,542) | 121,584 | (100,290) | ||
| Comprehensive loss, net of tax, attributable to parent: | (140,235) | (439,010) | (452,024) | (280,767) | (88,068) | (164,079) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.